BioCentury | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
BioCentury | Jun 13, 2018
Company News

Management tracks: Salk Institute, Galectin

The Board of Trustees for the Salk Institute for Biological Studies (La Jolla, Calif.) said that cancer and gene therapy researcher Inder Verma has resigned. The institute had placed Verma on administrative leave in April...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BioCentury | Apr 6, 2018
Finance

Picking season

Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke to...
BioCentury | Mar 30, 2018
Company News

Takeda mulls Shire takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it is considering a takeout of Shire plc (LSE:SHP; NASDAQ:SHPG), a move the pharma believes would strengthen its core pipeline areas of focus while adding Shire's expertise in rare...
BioCentury | Mar 30, 2018
Clinical News

EU approval for alofisel to treat perianal fistulas

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said the European Commission approved an MAA for Alofisel darvadstrocel to treat complex perianal fistulas in patients with Crohn's disease. The companies said Alofisel is...
BioCentury | Mar 28, 2018
Company News

Shire posts big gain as Takeda mulls takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it is considering a takeout of Shire plc (LSE:SHP; NASDAQ:SHPG), a move the pharma believes would strengthen its core pipeline areas of focus while adding Shire's expertise in rare...
BioCentury | Mar 23, 2018
Company News

EU approval for Alofisel to treat perianal fistulas

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said the European Commission approved an MAA for Alofisel darvadstrocel to treat complex perianal fistulas in patients with Crohn’s disease. The companies said Alofisel is...
BioCentury | Jan 12, 2018
Company News

Takeda acquiring TiGenix for €520M

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will acquire TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) for €1.78 per share in cash, or €520 million ($617.6 million). The price is an 82% premium to TiGenix’ close of €0.98...
Items per page:
1 - 10 of 127